VICTOR CHANDLER TWITTY November 5, 1901 – March 22, 1967
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Overruling the Food and Drug Administration
Overruling the Food and Drug Administration: An Analysis of the 2011 Denial of Over-the-Counter Status for Plan B Placed within the Historical Context of Executive Influence on FDA Action The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Alisha Crovetto, Overruling the Food and Drug Administration: An Analysis of the 2011 Denial of Over-the-Counter Status for Plan B Placed within the Historical Context of Executive Influence on FDA Action (May 2012). Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10985168 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Overruling the Food and Drug Administration: An Analysis of the 2011 Denial of Over-the-Counter Status for Plan B Placed within the Historical Context of Executive Influence on FDA Action Alisha Crovetto Harvard Law School J.D. Candidate, 2013 May 2012 Food & Drug Law Course Paper Abstract On December 7, 2011, newspaper headlines from coast to coast announced that Plan B One-Step, a form of emergency contraception, would not be made available to females under seventeen without a prescription. The denial of over-the-counter (“OTC”) status, though newsworthy itself, drew particular attention because of the unusual nature of the decision. As the New York Times announced, “[f]or the first time ever, the Health and Human Services secretary publicly overruled the Food and Drug Administration . -
Masakazu Konishi
Masakazu Konishi BORN: Kyoto, Japan February 17, 1933 EDUCATION: Hokkaido University, Sapporo, Japan, B.S. (1956) Hokkaido University, Sapporo, Japan, M.S. (1958) University of California, Berkeley, Ph.D. (1963) APPOINTMENTS: Postdoctoral Fellow, University of Tübingen, Germany (1963–1964) Postdoctoral Fellow, Division of Experimental Neurophysiology, Max-Planck Institut, Munich, Germany (1964–1965) Assistant Professor of Biology, University of Wisconsin, Madison (1965–1966) Assistant Professor of Biology, Princeton University (1966–1970) Associate Professor of Biology, Princeton University (1970–1975) Professor of Biology, California Institute of Technology (1975– 1980) Bing Professor of Behavioral Biology, California Institute of Technology (1980– ) HONORS AND AWARDS (SELECTED): Member, American Academy of Arts and Sciences (1979) Member, National Academy of Sciences (1985) President, International Society for Neuroethology (1986—1989) F. O. Schmitt Prize (1987) International Prize for Biology (1990) The Lewis S. Rosenstiel Award, Brandeis University (2004) Edward M. Scolnick Prize in Neuroscience, MIT (2004) Gerard Prize, the Society for Neuroscience (2004) Karl Spencer Lashley Award, The American Philosophical Society (2004) The Peter and Patricia Gruber Prize in Neuroscience, The Society for Neuroscience (2005) Masakazu (Mark) Konishi has been one of the leaders in avian neuroethology since the early 1960’s. He is known for his idea that young birds initially remember a tutor song and use the memory as a template to guide the development of their own song. He was the fi rst to show that estrogen prevents programmed cell death in female zebra fi nches. He also pioneered work on the brain mechanisms of sound localization by barn owls. He has trained many students and postdoctoral fellows who became leading neuroethologists. -
The Need to Shorten the Prescription Drug Approval Process
Valparaiso University Law Review Volume 27 Number 1 Fall 1992 pp.95-137 Fall 1992 Getting There First With the Best: The Need to Shorten the Prescription Drug Approval Process Mark A. Kassel Follow this and additional works at: https://scholar.valpo.edu/vulr Part of the Law Commons Recommended Citation Mark A. Kassel, Getting There First With the Best: The Need to Shorten the Prescription Drug Approval Process, 27 Val. U. L. Rev. 95 (1992). Available at: https://scholar.valpo.edu/vulr/vol27/iss1/3 This Notes is brought to you for free and open access by the Valparaiso University Law School at ValpoScholar. It has been accepted for inclusion in Valparaiso University Law Review by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at [email protected]. Kassel: Getting There First With the Best: The Need to Shorten the Presc Notes GETTING THERE FIRST WITH THE BEST: THE NEED TO SHORTEN THE PRESCRIPTION DRUG APPROVAL PROCESS I. INTRODUCTION Due to unnecessary time delays, high costs and safety concerns, drug regulation in the United States is in need of reform.' The United States consistently lags behind the rest of the developed world in the approval of new, innovative, and efficient medications.2 Therefore, the Food and Drug Administration (FDA) needs to implement creative and effective changes in the prescription drug approval process3 in order to protect the health of the American public. Most Americans think that the FDA's stringent process for approving new prescription drugs guarantees that prescription drugs are successfully monitored.4 The American public assumes that safe and innovative drugs are made available to the public as quickly' and cost effectively6 as possible, while unsafe7 products are kept off the market.' However, this confidence placed in the FDA is unwarranted. -
Germ-Line Gene Editing and Congressional Reaction in Context: Learning from Almost 50 Years of Congressional Reactions to Biomedical Breakthroughs
Journal of Law and Health Volume 30 Issue 1 Article 2 7-1-2017 Germ-Line Gene Editing and Congressional Reaction in Context: Learning From Almost 50 Years of Congressional Reactions to Biomedical Breakthroughs Russell A. Spivak, J.D. Harvard Law School I. Glenn Cohen, J.D. Harvard Law School Eli Y. Adashi, M.D., M.S. Brown University Follow this and additional works at: https://engagedscholarship.csuohio.edu/jlh Part of the Bioethics and Medical Ethics Commons, Cells Commons, Genetic Processes Commons, Health Law and Policy Commons, Medical Genetics Commons, Medical Jurisprudence Commons, Science and Technology Law Commons, and the Tissues Commons How does access to this work benefit ou?y Let us know! Recommended Citation Russell A. Spivak, J.D.; I. Glenn Cohen, J.D.; and Eli Y. Adashi, M.D., M.S., Germ-Line Gene Editing and Congressional Reaction in Context: Learning From Almost 50 Years of Congressional Reactions to Biomedical Breakthroughs, 30 J.L. & Health 20 (2017) available at https://engagedscholarship.csuohio.edu/jlh/vol30/iss1/2 This Article is brought to you for free and open access by the Journals at EngagedScholarship@CSU. It has been accepted for inclusion in Journal of Law and Health by an authorized editor of EngagedScholarship@CSU. For more information, please contact [email protected]. GERM-LINE GENE EDITING AND CONGRESSIONAL REACTION IN CONTEXT: LEARNING FROM ALMOST 50 YEARS OF CONGRESSIONAL REACTIONS TO BIOMEDICAL BREAKTHROUGHS RUSSELL A. SPIVAK, J.D., HARVARD LAW SCHOOL, CLASS OF 2017 I. GLENN COHEN J.D., PROFESSOR OF LAW, HARVARD LAW SCHOOL, CO-DIRECTOR, PETRIE- FLOM CENTER FOR HEALTH LAW POLICY, BIOTECHNOLOGY, AND BIOETHICS, HARVARD UNIVERSITY, CAMBRIDGE, MA. -
Balcomk41251.Pdf (558.9Kb)
Copyright by Karen Suzanne Balcom 2005 The Dissertation Committee for Karen Suzanne Balcom Certifies that this is the approved version of the following dissertation: Discovery and Information Use Patterns of Nobel Laureates in Physiology or Medicine Committee: E. Glynn Harmon, Supervisor Julie Hallmark Billie Grace Herring James D. Legler Brooke E. Sheldon Discovery and Information Use Patterns of Nobel Laureates in Physiology or Medicine by Karen Suzanne Balcom, B.A., M.L.S. Dissertation Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy The University of Texas at Austin August, 2005 Dedication I dedicate this dissertation to my first teachers: my father, George Sheldon Balcom, who passed away before this task was begun, and to my mother, Marian Dyer Balcom, who passed away before it was completed. I also dedicate it to my dissertation committee members: Drs. Billie Grace Herring, Brooke Sheldon, Julie Hallmark and to my supervisor, Dr. Glynn Harmon. They were all teachers, mentors, and friends who lifted me up when I was down. Acknowledgements I would first like to thank my committee: Julie Hallmark, Billie Grace Herring, Jim Legler, M.D., Brooke E. Sheldon, and Glynn Harmon for their encouragement, patience and support during the nine years that this investigation was a work in progress. I could not have had a better committee. They are my enduring friends and I hope I prove worthy of the faith they have always showed in me. I am grateful to Dr. -
Donald Griffin Was Able to Affect a Major Revolution in What Scien- Tists Do and Think About the Cognition of Nonhuman Ani- Mals
NATIONAL ACADEMY OF SCIENCES DONALD R. GRIFFIN 1915– 2003 A Biographical Memoir by CHARLES G. GROSS Any opinions expressed in this memoir are those of the author and do not necessarily reflect the views of the National Academy of Sciences. Biographical Memoirs, VOLUME 86 PUBLISHED 2005 BY THE NATIONAL ACADEMIES PRESS WASHINGTON, D.C. DONALD R. GRIFFIN August 3, 1915–November 7, 2003 BY CHARLES G. GROSS OST SCIENTISTS SEEK—but never attain—two goals. The M first is to discover something so new as to have been previously inconceivable. The second is to radically change the way the natural world is viewed. Don Griffin did both. He discovered (with Robert Galambos) a new and unique sensory world, echolocation, in which bats can perceive their surroundings by listening to echoes of ultrasonic sounds that they produce. In addition, he brought the study of animal consciousness back from the limbo of forbidden topics to make it a central subject in the contemporary study of brain and behavior. EARLY YEARS Donald R. (Redfield) Griffin was born in Southampton, New York, but spent his early childhood in an eighteenth- century farmhouse in a rural area near Scarsdale, New York. His father, Henry Farrand Griffin, was a serious amateur historian and novelist, who worked as a reporter and in advertising before retiring early to pursue his literary inter- ests. His mother, Mary Whitney Redfield, read to him so much that his father feared for his ability to learn to read. His favorite books were Ernest Thompson Seton’s animal 3 4 BIOGRAPHICAL MEMOIRS stories and the National Geographic Magazine’s Mammals of North America. -
The National Academies Committee on a New Government-University
NOTE: This is an unedited verbatim transcript of the Workshop on a New Government-University Partnership for Science and Security held at Stanford University on September 27-28, 2006. It was prepared by CASET Associates and is not an official report of The National Academies. Opinions and statements included in the transcript are solely those of the individual persons or participants at the workshop, and are not necessarily adopted or endorsed or verified as accurate by The National Academies. The National Academies Committee on a New Government-University Partnership for Science and Security September 28, 2006 Stanford University Bechtel Conference Center 616 Serra Mall, Encina Hall Stanford, CA Proceedings by: CASET Associates, Ltd. 10201 Lee Highway, suite 180 Fairfax, Virginia 22030 (703) 352-0091 NOTE: This is an unedited verbatim transcript of the Workshop on a New Government-University Partnership for Science and Security held at Stanford University on September 27-28, 2006. It was prepared by CASET Associates and is not an official report of The National Academies. Opinions and statements included in the transcript are solely those of the individual persons or participants at the workshop, and are not necessarily adopted or endorsed or verified as accurate by The National Academies. TABLE OF CONTENTS Page Introductions and Purpose of Meeting Jacques S. Gansler and Alice P. Gast 1 Security Concerns at National and University Laboratories Siegfried S. Hecker 3 Discussion 26 International Collaborations Jonathan Dorfan 40 Discussion 56 National Security and Academic Publishing Donald Kennedy 64 Discussion 77 Open Discussion: Moving Forward 86 NOTE: This is an unedited verbatim transcript of the Workshop on a New Government-University Partnership for Science and Security held at Stanford University on September 27-28, 2006. -
The FDAAA's New Website
Recipient of the Frances O. Kelsey Award for Courage and Excellence in Protecting the Public Health The FDAAA’s New Website (Still at www.fdaaa.org ) We are so pleased to unveil our new website. Not only is this modernized website more attractive and easier to follow, it has great new features such as members-only access to a growing collection of FDA- related information, a skills inventory, and the ability to chat with other members behind a secure firewall. This website will take us into a new era when FDAAA does even more to support your ongoing enrichment, connection to each other and to FDA, and your ability to locate resources, colleagues, friends, and experts. The FDA Alumni Association is the official global network of former and current FDA employees, connecting and supporting alumni, the Agency, and the public health community. Please be active in FDAAA and help us to make a difference. In speaking about FDAAA, then-Commissioner Ned Sharpless recently reminded us of a key quote from Margaret Mead: “Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it’s the only thing that ever has.” Members are encouraged to visit the Newsletter - Updates for the latest edition of the Newsletter, July 2020. Deb Autor, Chair Board of Directors FDA ALUMNI ASSOCIATION SAVE THE DATE…for our first FDA Alumni Association VIRTUAL Speaker Series Event! We are thrilled to have Dr. Luciana Borio (former Director for Medical and Biodefense Preparedness Policy for the White House National Security Council and former Acting Chief Scientist and Assistant Commissioner for Counterterrorism and Emerging Threats at FDA ) as our guest speaker on COVID-19 issues. -
Improving the Efficiency of the Later Stages of the Drug Development Process: Survey Results from the Industry, Academia, and the FDA
Improving the Efficiency of the Later Stages of the Drug Development Process: Survey Results from the Industry, Academia, and the FDA By Adrian Hedley Benjamin Gottschalk B.S. Biochemistry Texas A&M University, 1997 M.B.A. MIT Sloan School of Management, 2003 SUBMITTED TO THE HARVARD-MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE IN HEALTH SCIENCES AND TECHNOLOGY AT THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY JUNE 2004 © 2004 Massachusetts Institute of Technology All rights reserved Signature of Author: ____________________________________________________________ Harvard-MIT Division of Health Sciences and Technology May 7, 2004 Certified by: __________________________________________________________________ Ernst R. Berndt Professor of Applied Economics Thesis Co-supervisor Certified by: __________________________________________________________________ Joseph V. Bonventre Professor of Medicine and Health Sciences and Technology Co-Director, Harvard-MIT Division of Health Sciences and Technology Thesis Co-supervisor Accepted by: __________________________________________________________________ Martha Gray Professor of Medical and Electrical Engineering Co-Director, Harvard-MIT Division of Health Sciences and Technology Improving the Efficiency of the Later Stages of the Drug Development Process: Survey Results from the Industry, Academia, and the FDA By Adrian Hedley Benjamin Gottschalk Submitted to the Harvard-MIT Division of Health Sciences and Technology on May 7, 2004 in Partial Fulfillment of the Requirements for the Degree of Master of Science in Biomedical Enterprise ABSTRACT Drug development in the United States is a lengthy and expensive endeavor. It is estimated that average development times range from eleven to fifteen years and exceed costs of one billion dollars. The development pathway includes basic scientific discovery, pre-clinical testing in animals, clinical development in humans, and an application process. -
Regenerative Medicine's Historical Roots in Regeneration, Transplantation, and Translation
Developmental Biology 358 (2011) 278–284 Contents lists available at ScienceDirect Developmental Biology journal homepage: www.elsevier.com/developmentalbiology Regenerative medicine's historical roots in regeneration, transplantation, and translation Jane Maienschein Center for Biology and Society, School of Life Sciences 874501, Arizona State University, Tempe, AZ 85287-4501, United States article info abstract Article history: Regenerative medicine is not new; it has not sprung anew out of stem cell science as has often been Received for publication 4 February 2010 suggested. There is a rich history of study of regeneration, of development, and of the ways in which Revised 12 April 2010 understanding regeneration advances study of development and also has practical and medical applications. Accepted 9 June 2010 This paper explores the history of regenerative medicine, starting especially with T.H. Morgan in 1901 and Available online 16 June 2010 carrying through the history of transplantation research in the 20th century, to an emphasis on translational medicine in the late 20th century. Keywords: Regeneration © 2010 Elsevier Inc. All rights reserved. Development Translation Transplantation Regenerative medicine Regenerative medicine, as it has been labeled, typically calls for Yet, current research draws on several different lines of historical regeneration of lost function to address clinical medical problems. A study that have been grounded in different underlying assumptions widely adopted description recorded by the NIH captures several and have benefitted from different techniques and methods. At root different aspects of the research, noting the several goals to replace are studies of regeneration and transplantation, and it is worth lost structures, to regenerate failed functions, and to solve problems in looking more closely at those rich research traditions of the first half of new ways. -
Nobel Laureates in Physiology Or Medicine
All Nobel Laureates in Physiology or Medicine 1901 Emil A. von Behring Germany ”for his work on serum therapy, especially its application against diphtheria, by which he has opened a new road in the domain of medical science and thereby placed in the hands of the physician a victorious weapon against illness and deaths” 1902 Sir Ronald Ross Great Britain ”for his work on malaria, by which he has shown how it enters the organism and thereby has laid the foundation for successful research on this disease and methods of combating it” 1903 Niels R. Finsen Denmark ”in recognition of his contribution to the treatment of diseases, especially lupus vulgaris, with concentrated light radiation, whereby he has opened a new avenue for medical science” 1904 Ivan P. Pavlov Russia ”in recognition of his work on the physiology of digestion, through which knowledge on vital aspects of the subject has been transformed and enlarged” 1905 Robert Koch Germany ”for his investigations and discoveries in relation to tuberculosis” 1906 Camillo Golgi Italy "in recognition of their work on the structure of the nervous system" Santiago Ramon y Cajal Spain 1907 Charles L. A. Laveran France "in recognition of his work on the role played by protozoa in causing diseases" 1908 Paul Ehrlich Germany "in recognition of their work on immunity" Elie Metchniko France 1909 Emil Theodor Kocher Switzerland "for his work on the physiology, pathology and surgery of the thyroid gland" 1910 Albrecht Kossel Germany "in recognition of the contributions to our knowledge of cell chemistry made through his work on proteins, including the nucleic substances" 1911 Allvar Gullstrand Sweden "for his work on the dioptrics of the eye" 1912 Alexis Carrel France "in recognition of his work on vascular suture and the transplantation of blood vessels and organs" 1913 Charles R. -
Salome Gluecksohn-Waelsch 1907–2007
OBITUARY Salome Gluecksohn-Waelsch 1907–2007 Lee Silver Salome Waelsch, university professor emerita at Albert Einstein her embryological expertise with newfound genetic knowledge from College of Medicine in the Bronx, New York, died on November 7, her Columbia colleagues. In a series of papers published from 1938 2007, just a month after her 100th birthday. She was a remarkable onward, Salome presented a model for the action of the T-locus woman who persevered against Nazi anti-Semitism and Ivy League product as an inducer of mesoderm and axial development. Her sexism to establish the new scientific field of developmental genet- work effectively repudiated Spemann’s claim of the irrelevancy of ics. Her career was driven by an early insight into the fundamental genes to embryonic induction (which gave her great pleasure). Half connection between genes and development—a connection that a century later, Salome’s ideas would be validated at the molecular eluded the leading geneticists and embryologists of her time, who level when Bernhard Herrmann and Hans Lehrach characterized the seem not to have ventured intellectually beyond their narrow spheres T-locus product as a DNA binding protein that has a central role in of research. the regulation of transcription during the development of mesoderm Salome was born on October 6, 1907, in the town of Danzig, and notochord. Germany (now Gdansk, Poland). She studied zoology as an under- Salome experienced anti-Semitism firsthand in Nazi Germany, graduate and, beginning in 1928, worked as a graduate student with and then she experienced sexism firsthand in Ivy League America.